[Micrometastases in pediatric oncology]

Area of Science:

• Pediatric Oncology
• Cancer Cell Biology
• Diagnostic Technologies

Context:

• Metastatic relapse in pediatric solid tumors often stems from disseminated occult tumor cells present before initial treatment.
• Early detection of these micrometastases is crucial for accurate staging and personalized therapy in pediatric cancer patients.
• Monitoring residual disease post-treatment aids in adjusting adjuvant therapies like bone marrow transplantation or leukapheresis.

Purpose:

• To review recent advancements in sensitive immunocytochemical and molecular assays for detecting disseminated cancer cells.
• To discuss the clinical utility of identifying occult tumor cells in bone marrow and peripheral blood for various pediatric cancers.
• To evaluate the role of these detection techniques in ongoing and future clinical trials for childhood cancers.

Summary:

• Sensitive immunocytochemical and molecular assays can now identify disseminated cancer cells in bone marrow and peripheral blood.
• These techniques are applicable to pediatric cancers such as neuroblastoma, Ewing tumor, alveolar rhabdomyosarcoma, and primitive neuroectodermal tumors (PNETs).
• Focus is placed on technical achievements and the clinical relevance of detecting occult cancer cells for improved patient outcomes.

Impact:

• Improved diagnostic accuracy and staging for pediatric solid tumors.
• Enhanced ability to tailor adjuvant therapies, potentially improving survival rates.
• Facilitation of clinical trial design and patient stratification based on minimal residual disease.